LL-37: The Antimicrobial Peptide Under Research
LL-37 is the sole member of the human cathelicidin family, with antimicrobial, anti-biofilm, and immunomodulatory activities studied in infection, wound healing, and cancer biology.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
LL-37 is the only known human member of the cathelicidin family of antimicrobial peptides, with well-documented roles in innate immune defense, wound healing, and immunomodulatory signaling that extend far beyond direct microbial killing. This post reviews the peer-reviewed scientific literature on LL-37's mechanisms of action, biological roles across tissues, and its emerging and paradoxical role in cancer biology — all content is for research reference only and does not constitute medical advice or guidance for human use.
Cathelicidin Family and the CAMP Gene
Genomic Origin and Biosynthesis
LL-37 is encoded by the CAMP gene (Cathelicidin Antimicrobial Peptide) located on human chromosome 3. It is synthesized as an inactive precursor protein, hCAP18 (human cationic antimicrobial protein of 18 kDa), which is stored in neutrophil secondary granules and in lamellar bodies in epithelial cells. The precursor consists of a conserved N-terminal cathelin domain followed by the variable C-terminal antimicrobial peptide domain.
Active LL-37 is released by proteolytic cleavage of hCAP18 by neutrophil serine protease 3 (PR3) or by kallikreins in epithelial tissues, releasing the 37-amino-acid C-terminal peptide. The name "LL-37" derives from the double leucine residues at the N-terminus of the mature peptide and its 37-amino-acid length. Upon release, LL-37 adopts an amphipathic alpha-helical structure that is central to its mechanism of action at microbial membranes.
Cathelicidins are found throughout vertebrates, with structural diversity in the antimicrobial domain across species, but LL-37 is the sole human representative of this ancient peptide family.
Membrane Disruption Mechanism
Electrostatic Attraction and Membrane Insertion
The primary bactericidal mechanism of LL-37 relies on its strong cationic charge (net charge +6 at physiological pH) and amphipathic helical structure. Bacterial membranes are enriched in negatively charged phospholipids (phosphatidylglycerol, cardiolipin), creating electrostatic attraction for cationic antimicrobial peptides. Mammalian cell membranes, in contrast, are enriched in zwitterionic phospholipids (phosphatidylcholine) in the outer leaflet, providing relative selectivity against bacterial membranes.
Upon electrostatic binding, LL-37 inserts its hydrophobic face into the bacterial lipid bilayer. At sufficient surface concentrations, the peptide disrupts membrane integrity through either a "carpet" model (detergent-like dissolution of membrane integrity) or a "toroidal pore" model (transient pore formation with lipid flip-flop). The specific disruption mechanism appears to depend on membrane composition, peptide concentration, and target organism (Brogden, Nature Reviews Microbiology, 2005).
This membrane-based killing mechanism confers activity against a broad spectrum of microorganisms including Gram-positive bacteria, Gram-negative bacteria, fungi, and enveloped viruses, and does not require the specific receptor-binding targets exploited by conventional antibiotics, providing a mechanistic basis for retention of activity against antibiotic-resistant organisms.
Biofilm Disruption
A distinctive property of LL-37 relative to many conventional antibiotics is its ability to disrupt preformed microbial biofilms — structured microbial communities embedded in extracellular matrix that are notoriously resistant to most antimicrobial treatments. Overhage et al. (Infection and Immunity, 2008) demonstrated that sub-lethal concentrations of LL-37 inhibited Pseudomonas aeruginosa biofilm formation by interfering with quorum sensing signal (3-oxo-C12-HSL) binding, and that higher concentrations disrupted established biofilms by permeabilizing cells within the biofilm architecture.
This anti-biofilm activity has been studied in the context of chronic lung infections in cystic fibrosis patients, where P. aeruginosa biofilm colonization drives progressive pulmonary destruction. Research groups have explored LL-37-derived peptides with enhanced anti-biofilm activity as potential research tools for investigating biofilm biology and treatment strategies.
TLR4 Ligand Activity and Immunomodulation
Toll-Like Receptor Interaction
Beyond direct antimicrobial activity, LL-37 functions as an endogenous ligand and modulator of pattern recognition receptors, particularly Toll-like receptor 4 (TLR4). Li et al. (Journal of Immunology, 2010) demonstrated that LL-37 can directly bind lipopolysaccharide (LPS) and neutralize its TLR4-stimulatory activity, reducing pro-inflammatory cytokine production in macrophages exposed to gram-negative bacterial products.
LL-37 also directly activates various receptor-mediated signaling cascades in immune cells through non-TLR pathways, including the formyl peptide receptor 2 (FPR2/ALX) and G protein-coupled receptor 133 (P2X purinoceptors), with outcomes that include chemotactic recruitment of immune cells, mast cell degranulation modulation, and dendritic cell maturation effects.
Wound Healing: Keratinocyte Migration
One of the most well-characterized non-antimicrobial functions of LL-37 is its promotion of epithelial wound healing through effects on keratinocyte migration and proliferation.
Heilborn et al. (Journal of Investigative Dermatology, 2003) demonstrated that LL-37 is highly expressed in keratinocytes at the wound edge during skin healing, and that it stimulates keratinocyte migration (restitution) through transactivation of the epidermal growth factor receptor (EGFR) via shedding of heparin-binding EGF (HB-EGF). This growth factor receptor transactivation mechanism is distinct from direct EGFR ligand binding and represents a novel mechanism for peptide-mediated wound response.
In vitro scratch assay studies and in vivo wound healing models in mice with conditional CAMP gene disruption have confirmed the requirement for LL-37 in normal epidermal wound closure kinetics, with CAMP-knockout animals showing delayed reepithelialization following standardized excisional wounds.
Lung Infection Studies
In pulmonary innate defense, LL-37 is secreted by airway epithelial cells, alveolar macrophages, and submucosal gland cells in response to microbial challenge. Bals et al. (Journal of Clinical Investigation, 1998) established hCAP18/LL-37 as a constitutively expressed component of airway surface liquid with activity against respiratory pathogens.
Studies in patients with cystic fibrosis have documented that high-salt airway surface liquid conditions — characteristic of the CF airway environment — inhibit LL-37's antimicrobial activity, a finding that contributed to early understanding of why CF airways are susceptible to bacterial colonization despite LL-37 expression (Smith et al., Cell, 1996, in the related context of defensin salt sensitivity).
Influenza infection research has also documented that LL-37 can reduce viral replication and attenuate inflammatory responses in infected epithelial cells, with proposed mechanisms including direct virion membrane disruption and modulation of antiviral interferon signaling.
Cancer Biology: The Pro- and Anti-Tumor Paradox
Context-Dependent Oncological Effects
The cancer biology of LL-37 represents one of the most complex and unresolved aspects of its research portfolio, characterized by strikingly divergent effects across tumor types.
Pro-tumor effects have been documented in several cancer contexts. Coffelt et al. (Journal of Clinical Investigation, 2009) showed that LL-37 is produced by tumor-infiltrating neutrophils and promotes breast cancer cell proliferation, invasion, and angiogenesis through FPR2 receptor activation and downstream MAPK/ERK signaling. Similar pro-proliferative effects have been reported in ovarian cancer models, where LL-37 stimulates cancer cell growth and drug resistance.
Anti-tumor effects have been documented in other cancer types and experimental contexts. Li et al. (Biomedicine & Pharmacotherapy, 2018) and others have shown that LL-37 induces apoptosis in colon cancer and leukemia cell lines through mitochondrial membrane disruption — a mechanism analogous to its bacterial membrane activity. In melanoma models, LL-37 has been shown to recruit and activate natural killer cells and cytotoxic T cells through FPR2-mediated chemotaxis, promoting anti-tumor immune surveillance.
This paradox — pro-tumor in breast and ovarian contexts, anti-tumor in colorectal and hematological contexts — is currently attributed to differences in receptor expression profiles across tumor microenvironments, the complex role of FPR2 (which can mediate both pro-inflammatory and pro-resolving signals depending on the ligand and cellular context), and differences in the inflammatory status of the tumor microenvironment.
Psoriasis and Skin Autoimmunity
LL-37 plays a well-established pathogenic role in plaque psoriasis. Elevated LL-37 expression in psoriatic plaques has been documented relative to normal skin, and research by Lande et al. (Nature, 2007) demonstrated that LL-37 forms complexes with self-DNA released from necrotic keratinocytes, creating ligands that activate plasmacytoid dendritic cells (pDCs) via TLR7 and TLR9. This mechanism of breaking tolerance to self-nucleic acids through LL-37-mediated DNA complex formation has been proposed as a critical step in the initiation of the autoimmune cycle in psoriasis.
For related antimicrobial peptide research context, see the peptide library for other innate immune peptide entries in this database.
See also: LL-37 compound library entry
All content on ClinicalPeptide.org is intended exclusively for research reference. No content constitutes medical advice, clinical guidance, or recommendations for human use.